Rhenman & Partners Asset Management AB Increases Holdings in Janux Therapeutics, Inc. $JANX

Rhenman & Partners Asset Management AB increased its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 125.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 225,377 shares of the company’s stock after acquiring an additional 125,250 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Janux Therapeutics were worth $3,110,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. California State Teachers Retirement System raised its position in Janux Therapeutics by 1.1% in the second quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after purchasing an additional 404 shares during the period. Nuveen LLC raised its position in Janux Therapeutics by 0.8% in the fourth quarter. Nuveen LLC now owns 96,416 shares of the company’s stock valued at $1,331,000 after purchasing an additional 787 shares during the period. Congress Asset Management Co. raised its position in Janux Therapeutics by 2.8% in the fourth quarter. Congress Asset Management Co. now owns 57,342 shares of the company’s stock valued at $791,000 after purchasing an additional 1,569 shares during the period. ProShare Advisors LLC raised its position in Janux Therapeutics by 18.3% in the fourth quarter. ProShare Advisors LLC now owns 10,495 shares of the company’s stock valued at $145,000 after purchasing an additional 1,621 shares during the period. Finally, Kennedy Capital Management LLC raised its position in Janux Therapeutics by 20.0% in the third quarter. Kennedy Capital Management LLC now owns 11,413 shares of the company’s stock valued at $279,000 after purchasing an additional 1,905 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 0.7%

JANX stock opened at $13.56 on Friday. The company has a market capitalization of $826.89 million, a PE ratio of -7.37 and a beta of 2.53. Janux Therapeutics, Inc. has a 12-month low of $12.12 and a 12-month high of $35.34. The business’s fifty day moving average price is $14.49 and its 200 day moving average price is $15.03.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. Research analysts predict that Janux Therapeutics, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Janeen Noel Doyle sold 4,059 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the sale, the insider owned 75,941 shares in the company, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $14.17, for a total value of $28,878.46. Following the completion of the sale, the vice president owned 32,270 shares in the company, valued at $457,265.90. This represents a 5.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

JANX has been the topic of a number of research analyst reports. Barclays downgraded Janux Therapeutics from an “overweight” rating to an “underweight” rating and reduced their target price for the company from $29.00 to $14.00 in a research report on Monday, April 20th. Piper Sandler reduced their target price on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Weiss Ratings upgraded Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 22nd. Finally, Evercore set a $22.00 target price on Janux Therapeutics in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.85.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.